BioCryst Pharmaceuticals, Inc.

BioCryst Pharmaceuticals, Inc.verified

BCRX

Price:

$6

Market Cap:

$1.24B

BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, w...[Read more]

Industry

Biotechnology

IPO Date

1994-03-04

Stock Exchange

NASDAQ

Ticker

BCRX

The PE Ratio as of June 2024 (TTM) for BioCryst Pharmaceuticals, Inc. (BCRX) is -5.61

According to BioCryst Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -5.61. This represents a change of -13.51% compared to the average of -6.49 of the last 4 quarters.

BioCryst Pharmaceuticals, Inc. (BCRX) Historical PE Ratio (quarterly & annually)

How has BCRX PE Ratio performed in the past?

The mean historical PE Ratio of BioCryst Pharmaceuticals, Inc. over the last ten years is -9.53. The current -5.61 PE Ratio has changed 5.79% with respect to the historical average. Over the past ten years (40 quarters), BCRX's PE Ratio was at its highest in in the June 2015 quarter at 55.32. The PE Ratio was at its lowest in in the December 2019 quarter at -43.19.

Quarterly (TTM)
Annual

Average

-9.53

Median

-8.34

Minimum

-17.97

Maximum

-3.32

BioCryst Pharmaceuticals, Inc. (BCRX) PE Ratio by Quarter and Year

Discovering the peaks and valleys of BioCryst Pharmaceuticals, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 112.60%

Maximum Annual PE Ratio = -3.32

Minimum Annual Increase = -59.61%

Minimum Annual PE Ratio = -17.97

Quarterly (TTM)
Annual
YearPE RatioChange
2023-5.08-41.16%
2022-8.64-35.92%
2021-13.48112.60%
2020-6.3490.85%
2019-3.32-59.61%
2018-8.2230.47%
2017-6.30-25.49%
2016-8.46-51.63%
2015-17.49-2.67%
2014-17.9728.92%

BioCryst Pharmaceuticals, Inc. (BCRX) Average PE Ratio

How has BCRX PE Ratio performed in the past?

The current PE Ratio of BioCryst Pharmaceuticals, Inc. (BCRX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

-9.07

5-year avg

-7.37

10-year avg

-9.53

BioCryst Pharmaceuticals, Inc. (BCRX) PE Ratio vs. Peers

How is BCRX’s PE Ratio compared to its peers?

BioCryst Pharmaceuticals, Inc.’s PE Ratio is less than TG Therapeutics, Inc. (59.52), greater than Axsome Therapeutics, Inc. (-12.16), greater than Intercept Pharmaceuticals, Inc. (-13.55), less than Seres Therapeutics, Inc. (-1.26), greater than Madrigal Pharmaceuticals, Inc. (-12.43), less than Kezar Life Sciences, Inc. (-0.47), less than Immunic, Inc. (-1.07), less than Atara Biotherapeutics, Inc. (-0.24), less than Pieris Pharmaceuticals, Inc. (-0.70), greater than Apellis Pharmaceuticals, Inc. (-11.81), greater than Blueprint Medicines Corporation (-22.79), greater than Karuna Therapeutics, Inc. (-29.52), less than Mirati Therapeutics, Inc. (-5.32), less than Day One Biopharmaceuticals, Inc. (-5.55), greater than Anavex Life Sciences Corp. (-7.88), greater than Cassava Sciences, Inc. (-17.51), less than INmune Bio, Inc. (-4.02), less than BioVie Inc. (-0.55), less than Cognition Therapeutics, Inc. (-2.36), greater than Viking Therapeutics, Inc. (-55.90), less than X4 Pharmaceuticals, Inc. (-1.50), less than PDS Biotechnology Corporation (-2.17),

Build a custom stock screener for BioCryst Pharmaceuticals, Inc. (BCRX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like BioCryst Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

BioCryst Pharmaceuticals, Inc. (BCRX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like BioCryst Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the PE Ratio?

How can you use the PE Ratio?

What is BioCryst Pharmaceuticals, Inc.'s PE Ratio?

How is the PE Ratio calculated for BioCryst Pharmaceuticals, Inc. (BCRX)?

What is the highest PE Ratio for BioCryst Pharmaceuticals, Inc. (BCRX)?

What is the 3-year average PE Ratio for BioCryst Pharmaceuticals, Inc. (BCRX)?

What is the 5-year average PE Ratio for BioCryst Pharmaceuticals, Inc. (BCRX)?

How does the current PE Ratio for BioCryst Pharmaceuticals, Inc. (BCRX) compare to its historical average?